Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 99.1B 357M 320M 298M 271M 510M 34.17B 514M 3.59B 1.4B 17.63B 1.34B 1.31B 56.75B P/E 2026 *
9.37x
P/E 2027 * 7.79x
Enterprise Value 99.1B 357M 320M 298M 271M 510M 34.17B 514M 3.59B 1.4B 17.63B 1.34B 1.31B 56.75B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.33x
Free-Float
16.89%
Yield 2026 *
5.8%
Yield 2027 * 6.69%
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
29/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026, Payable on September 11, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-1.45%
1 week+1.36%
Current month-0.30%
1 month+2.00%
3 months-16.36%
6 months-15.24%
Current year-19.95%
1 week 310
Extreme 310
317.98
1 month 299.8
Extreme 299.8
326.05
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.27
3 years 74
Extreme 74
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%+1.36%-27.44%+305.19% 358M
-0.61%+1.59%+43.50%+93.02% 1,054B
-5.45%-1.84%+31.01%+59.45% 636B
-1.37%+4.25%+20.73%+87.91% 497B
-1.36%+1.27%+67.72%+38.20% 359B
+0.04%+3.03%+24.23%+41.31% 345B
-0.52%+2.03%+14.41%+36.61% 273B
-1.07%-0.20%-6.21%+8.75% 246B
-0.28%+3.79%+42.90%+47.08% 226B
-1.36%+3.17%+25.88%+91.63% 187B
Average -1.27%+2.75%+23.67%+80.91% 382.26B
Weighted average by Cap. -1.48%+3.19%+32.81%+64.74%

Financials

2026 *2027 *
Net sales 68.81B 248M 222M 207M 188M 354M 23.73B 357M 2.49B 974M 12.24B 932M 912M 39.4B 74.58B 269M 241M 224M 204M 384M 25.72B 386M 2.7B 1.06B 13.27B 1.01B 988M 42.7B
Net income 10.49B 37.84M 33.87M 31.58M 28.64M 54.02M 3.62B 54.36M 379M 149M 1.87B 142M 139M 6.01B 12.42B 44.8M 40.11M 37.39M 33.91M 63.96M 4.28B 64.36M 449M 176M 2.21B 168M 165M 7.11B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pakistan Limited
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
13/10/26 PKR 311.19 -0.26% 62,009
12/10/26 PKR 312.00 -1.45% 63,979
09/10/26 PKR 316.60 +1.20% 138,904
08/10/26 PKR 312.85 -0.55% 54,661
07/10/26 PKR 314.59 +0.03% 56,438
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
312.00PKR
Average target price
510.00PKR
Spread / Average Target
+63.46%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GlaxoSmithKline Pakistan Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock